IMV Key Statistics, Chart & Performance
The current stock price of IMV is 0.8225 USD. In the past month the price increased by 52.46%. In the past year, price decreased by -93.09%.
IMV Latest News, Press Relases and Analysis
IMV Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.7 | 395.86B | ||
| AMGN | AMGEN INC | 14.51 | 170.90B | ||
| GILD | GILEAD SCIENCES INC | 15.04 | 152.86B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.69 | 113.14B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.59 | 78.49B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 809.08 | 54.51B | ||
| INSM | INSMED INC | N/A | 41.64B | ||
| NTRA | NATERA INC | N/A | 31.89B | ||
| BIIB | BIOGEN INC | 10.3 | 25.31B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.51 | 21.04B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.24B | ||
| INCY | INCYTE CORP | 14.97 | 18.87B |
Related stock screener links
About IMV
Company Profile
IMV, Inc. is a clinical-stage biopharmaceutical company, which engage in providing a novel class of cancer immunotherapies and vaccines against infectious diseases including COVID-19. The company is headquartered in Dartmouth, Nova Scotia and currently employs 63 full-time employees. The company went IPO on 2007-10-24. The firm is focused on developing a portfolio of therapies based on DPX, an immune-educating technology platform, that is designed to inform a specific anti-tumor immune response, offering benefit to patients with solid or hematological cancers. Its lead candidate, maveropepimut-S (MVP-S) is a DPX-based immunotherapy that targets survivin-expressing cells for elimination by educated, cytotoxic T cells. Its other candidates include DPX-RSV and DPX-COVID-19. DPX-RSV is a DPX-based vaccine candidate targeting the respiratory syncytial virus (RSV) strain A. The company is focused on developing DPX-COVID-19, a vaccine candidate against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by using its DPX platform. The firm is also developing maveropepimut-S for the treatment of breast and ovarian cancer, as well as for Diffuse large B-cell lymphoma (DLBCL) and other malignancies.
Company Info
IMV INC
130 Eileen Stubbs Ave Suite 19
Dartmouth NOVA SCOTIA B3B 2C4 CA
CEO: Frederic Ors
Employees: 63
Phone: 19024921819.0
IMV INC / IMV FAQ
What does IMV INC do?
IMV, Inc. is a clinical-stage biopharmaceutical company, which engage in providing a novel class of cancer immunotherapies and vaccines against infectious diseases including COVID-19. The company is headquartered in Dartmouth, Nova Scotia and currently employs 63 full-time employees. The company went IPO on 2007-10-24. The firm is focused on developing a portfolio of therapies based on DPX, an immune-educating technology platform, that is designed to inform a specific anti-tumor immune response, offering benefit to patients with solid or hematological cancers. Its lead candidate, maveropepimut-S (MVP-S) is a DPX-based immunotherapy that targets survivin-expressing cells for elimination by educated, cytotoxic T cells. Its other candidates include DPX-RSV and DPX-COVID-19. DPX-RSV is a DPX-based vaccine candidate targeting the respiratory syncytial virus (RSV) strain A. The company is focused on developing DPX-COVID-19, a vaccine candidate against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by using its DPX platform. The firm is also developing maveropepimut-S for the treatment of breast and ovarian cancer, as well as for Diffuse large B-cell lymphoma (DLBCL) and other malignancies.
What is the current price of IMV stock?
The current stock price of IMV is 0.8225 USD. The price decreased by -2.55% in the last trading session.
Does IMV INC pay dividends?
IMV does not pay a dividend.
What is the ChartMill technical and fundamental rating of IMV stock?
IMV has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What do analysts say about IMV INC (IMV) stock?
7 analysts have analysed IMV and the average price target is 21.8 USD. This implies a price increase of 2550.76% is expected in the next year compared to the current price of 0.8225.
Can you provide the market cap for IMV INC?
IMV INC (IMV) has a market capitalization of 9.63M USD. This makes IMV a Nano Cap stock.
IMV Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to IMV. When comparing the yearly performance of all stocks, IMV is a bad performer in the overall market: 98.15% of all stocks are doing better.
IMV Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to IMV. IMV has a bad profitability rating. Also its financial health evaluation is rather negative.
IMV Financial Highlights
Over the last trailing twelve months IMV reported a non-GAAP Earnings per Share(EPS) of -4.59. The EPS increased by 4.44% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
IMV Forecast & Estimates
7 analysts have analysed IMV and the average price target is 21.8 USD. This implies a price increase of 2550.76% is expected in the next year compared to the current price of 0.8225.
For the next year, analysts expect an EPS growth of 20.34% and a revenue growth -80.66% for IMV